ArticleEpilepsy currents2026
Bitemporal Lobe Epilepsy: Evolving Diagnostic and Treatment Paradigms.
Article in Epilepsy currents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent.Signal transduction and targeted therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilateral temporal lobe epilepsy (BTLE) represents a challenging subset of drug-resistant epilepsy, accounting for 20-35% of temporal lobe epilepsy cases. Characterized by independent seizure onset from both temporal lobes, BTLE complicates diagnosis and treatment due to the difficulty in precisely localizing seizure onset zones (SOZs) and its profound cognitive and quality-of-life impact. Memory impairment and frequent seizures significantly burden patients, necessitating advanced diagnostic and therapeutic strategies. Traditional scalp EEG often reveals bilateral ictal patterns but lacks specificity to confirm independent seizure foci. Stereoelectroencephalography remains the gold standard for accurate SOZ localization in BTLE, supported by comprehensive semiological and neuropsychological assessments. Understanding the structural and functional connectivity of the temporal lobes is essential for tailored management. Surgical resection is generally discouraged in BTLE owing to modest seizure control and high risk of cognitive decline. However, unilateral resection may benefit selected patients with pronounced seizure laterality (≥80%), though data remain inconsistent. Neuromodulation therapies, including vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation (RNS), have emerged as promising alternatives, demonstrating responder rates around 70%. Notably, RNS offers unique advantages by enabling long-term monitoring to refine seizure laterality and potentially guide future surgical decisions. Despite these advances, access to neuromodulation remains limited in many settings. BTLE continues to pose diagnostic and therapeutic challenges, emphasizing the need for ongoing research to optimize individualized approaches and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.